Kyverna Therapeutics, Inc.
KYTX
Rank in Stocks
#14618
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Share Price
$5.03
Last synced: 2026-11-12
Market Cap
$311.66M
Change (1 day)
-1.76%
Change (1 year)
-22.38%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Kyverna Therapeutics, Inc. (KYTX)
Category
Healthcare
EPS for Kyverna Therapeutics, Inc. (KYTX)
EPS as of June 2026 TTM: $-2.94
According to Kyverna Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-2.94. At the end of 2025 the company had an EPS of $-3.64, a decrease compared to its 2024 EPS of $-3.33.
EPS history for Kyverna Therapeutics, Inc. from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.94 | -19.23% |
| 2025 | $-3.64 | 9.31% |
| 2024 | $-3.33 | 3,329,900.00% |
| 2023 | 0.00 | -99.99% |
| 2022 | $-1.12 | 9.80% |
| 2021 | $-1.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -632.65% |
US
|
|
| $-7.07 | 140.48% |
US
|
|
| $-5.29 | 79.93% |
AU
|
|
| $12.88 | -538.10% |
BE
|
|
| $21.56 | -833.33% |
NL
|
Questions about Kyverna Therapeutics, Inc.'s earnings per share (EPS)
What is Kyverna Therapeutics, Inc.'s earnings per share (EPS)?
Kyverna Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-2.94, as of Jun 2026.
What was Kyverna Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Kyverna Therapeutics, Inc.'s earnings per share (EPS) was $-3.64, compared with $-3.33 in 2024.
How has Kyverna Therapeutics, Inc.'s earnings per share (EPS) changed since 2021?
From 2021 to 2025, Kyverna Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 (0.00) and lowest in 2025 ($-3.64).
How does Kyverna Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Kyverna Therapeutics, Inc.'s earnings per share (EPS) ($-2.94) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.